SAN Share Price

Open 88.34 Change Price %
High 88.88 1 Day -0.78 -0.88
Low 87.87 1 Week 2.81 3.30
Close 87.87 1 Month 0.27 0.31
Volume 2401275 1 Year 18.39 26.47
52 Week High 92.97
52 Week Low 66.72
SAN Important Levels
Resistance 2 88.81
Resistance 1 88.42
Pivot 88.21
Support 1 87.32
Support 2 86.93
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
BRS 12.00 0.00%
BRS 12.00 0.00%
More..
EPA France Top Gainers Stocks
MLKRI 3.43 20.77%
APAM 33.78 15.72%
APAM 33.78 15.72%
MLLOI 3.80 15.15%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
More..
EPA France Top Losers Stocks
ALDOL 15.00 -58.32%
MLATV 2.00 -33.33%
MLPHW 0.70 -21.35%
MLNEI 0.91 -16.51%
ALALO 0.08 -11.11%
MLAAE 4.49 -9.84%
MLHMC 3610.00 -8.38%
MLDEX 1.50 -7.41%
FED 12.55 -6.90%
FED 12.55 -6.90%
More..

Sanofi (EPA: SAN)

SAN Technical Analysis 3
As on 23rd Jun 2017 SAN Share Price closed @ 87.87 and we RECOMMEND Buy for LONG-TERM with Stoploss of 77.78 & Buy for SHORT-TERM with Stoploss of 87.07 we also expect STOCK to react on Following IMPORTANT LEVELS.
SAN Target for June
1st Target up-side 91.52
2nd Target up-side 93.87
3rd Target up-side 96.22
1st Target down-side 84.82
2nd Target down-side 82.47
3rd Target down-side 80.12
SAN Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.sanofi-aventis.com
SAN Address
SAN
54, Rue La Bo
Paris, 75008
France
Phone: 33 1 53 77 40 00
SAN Latest News
Interactive Technical Analysis Chart Sanofi ( SAN EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Sanofi
SAN Business Profile
Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Its products include Lantus and Apidra analogs of human insulin; Insuman human insulin solutions and suspensions; Amaryl, a sulfonylurea; BGStar, iBGStar, and MyStar Extra blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme, for mucopolysaccharidosis Type I; Aubagio, a immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company’s products also comprise thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has strategic alliances with Bristol-Myers Squibb, Regeneron, Warner Chilcott, and Regulus Therapeutics Inc., as well as a strategic collaboration with UCB S.A. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.